Clinical Trial Update: TD-0903 for ALI Associated With COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 trial update for TD-0903 in acute lung injury and lung inflammation associated with COVID-19 has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Inflammation Associated with COVID-19
• Lung Injury

Drugs mentioned

• TD-0903

Snippet

Sponsor: Theravance Biopharma | Conditions: Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19 | Phase 2 | Status: COMPLETED | Results posted: 2022-03-17